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Bilateral vestibular hypofunction in
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Jonathan H. Smith, MD; Kyndra C. Stovall, PhD; Stephen Coons, MD;
Terry Douglas Fife, MD

Abstract

We describe the case of a 59-year-old woman who presented
with progressive bilateral vestibular hypofunction and who
was found to have bilateral granulomatous mass lesions
of the mesial temporal lobe. Initially, her condition stabilized neurologically with corticosteroids, but a diagnosis
of neurosarcoidosis was delayed because of the unusual
presentation and persistently normal chest imaging results
and serum angiotensin-converting enzyme (ACE) levels.
Approximately 1 year after her initial presentation, the
patient died of complications of a myocardial infarction and
pulmonary embolism. Sarcoidosis should be considered in
the differential diagnosis of idiopathic bilateral vestibular
hypofunction even if the chest imaging and serum ACE
levels are normal, particularly when there is evidence of
a multisystem process.
Introduction

Sarcoidosis is a chronic multisystem granulomatous
disorder of unclear etiology. Pathologically, it features
diseased tissue that is characterized by the presence of
epithelioid, noncaseating granulomas. Neurosarcoidosis is a rare manifestation of this disease, clinically
affecting only 5% of all patients with sarcoidosis.1 The
most common neurologic feature of neurosarcoidosis
is cranial neuropathy, which is attributable to frequent
granulomatous involvement of the basal leptomeninges.
Parenchymatous disease may also occur, most often in
the hypothalamus and the pituitary gland.2
Audiovestibular dysfunction in neurosarcoidosis is
rare. In an extensive review of neurosarcoidosis case
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reports, Colvin found that 28 of 31 patients (90%) for
whom audiometric data were available had experienced
either a sudden or rapidly progressive hearing loss.3
Among 24 patients who had undergone vestibular
function testing, 23 had abnormal results; of these 23,
6 had unilateral and 16 had bilateral loss of vestibular
function (the remaining patient’s study was nonlocalizing). Vestibular impairment in the absence of hearing
loss may also occur.4
In this article, we describe an unusual case of neurosarcoidosis that featured the rare manifestation of
bilateral vestibular dysfunction in the absence of auditory impairment.
Case report

A 59-year-old woman presented with a 4-month history
of progressive gait imbalance without vertigo. Examination showed a widened gait base and poor balance.
Hearing, speech, articulation, and vision were normal.
Magnetic resonance imaging (MRI) of the brain demonstrated an increased signal on gadolinium-enhanced
T1-weighted imaging in the mesial right temporal lobe
and minimal change in the left temporal lobe (figure
1, A). A diagnosis of herpes simplex encephalitis was
entertained along with other infectious, inflammatory,
and neoplastic etiologies. Cerebrospinal fluid (CSF)
studies revealed 14 white blood cells/µl, which were
100% lymphocytes; a CSF glucose level of 57 mg/dl;
and a CSF protein concentration of 52 mg/dl. Bacterial
and fungal cultures were negative, as was a polymerase
chain reaction assay for herpes simplex in CSF. In addition, findings on CSF VDRL testing, coccidioides
serology, cerebral angiography, and chest x-ray were all
normal. Electroencephalography (EEG) showed bitemporal slowing, but no epileptiform changes. The serum
angiotensin-converting enzyme (ACE) level (17 U/L)
and serum calcium concentration (9.7 mg/dl) were both
within normal limits. A purified protein derivative of a
www.entjournal.com ■ E1
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tuberculin skin test was nega- A
B
tive, but the patient was anergic
to mumps.
An excisional biopsy of the
right temporal lobe revealed
lymphoplasmacytic inflammation with noncaseating granulomas, clusters of fibroblasts and
histiocytes, and multinucleated
giant cells (figure 2). No cultures
grew from the specimen. Antimicrobial therapy was given em- Figure 1. A: Coronal T1-weighted MRI 4 months after the onset of symptoms shows gadolinium
pirically; it included ceftriaxone, enhancement of the mesial temporal lobe lesions. B: A similar view at 7 months shows postoperaacyclovir, isoniazid, rifampin, tive changes in the right temporal lobe.
ethambutol, and pyrazinamide.
The patient was also started on dexamethasone at 8 mg was observed. Five months later, she died from comtwice daily.
plications of a myocardial infarction and pulmonary
At a follow-up appointment 2 months later, the embolism.
patient had shown some improvement in her balance,
and a repeat MRI demonstrated a partial resolution Discussion
of the right temporal lesion. The decision was made In this case, the initial complaint was of imbalance,
to taper the steroids and continue the antimicrobial which was most likely caused by the progressive bilateral
therapy. However, 2 weeks later (and 7 months after vestibular dysfunction. Bilateral vestibular hypofunction
her initial onset of imbalance), the patient returned may present without nystagmus, nausea, or vertigo, parwith complaints of acute amnesia and confusion. She ticularly if the loss of function occurs symmetrically or
said she woke up feeling that she had “lost one and a gradually. Sakakibara et al reported a case of vestibular
half years” of memory. On examination, her attention dysfunction that produced progressive ataxia, but that
and registration were good, but her recall was poor. She case also featured some element of communicating
was completely unaware of the events that had led to hydrocephalus that might have contributed to the
her current health situation. She exhibited delusional ataxia.5
thinking at times. Prior to her current situation, she
Loss of vestibular function has been reported both
had no history of behavioral change or cognitive deficit. with5-10 and without4 hearing loss. Hearing loss secondary
Her dizziness had also progressed to the point where to sarcoidosis is often bilateral and frequently associated
she felt unable to sit up. A repeat MRI demonstrated with fluctuating hearing. In an extensive review of the
significant progression of the left temporal lesion and literature, Mende and Suchenwirth found hearing loss in
a slight enlargement of the area of signal change in the 12.2% of patients with neurosarcoidosis and nystagmus
hippocampal area on the right side (figure 1, B). Repeat in 8.6%.11 On the other hand, Hybels and Rice found
EEG monitoring revealed generalized slowing and no audiovestibular dysfunction to be more common.12
seizures, but phenytoin was started empirically. Com- Colvin’s review of 48 case reports and 2 additional cases
puted tomography (CT) scans of the chest, abdomen, found normal hearing in only 1 of 22 patients for whom
and pelvis were negative. A gallium scan demonstrated pure-tone audiometric data were available, suggesting
focal uptake in the hila of both lungs consistent with that vestibular loss with spared hearing is quite rare
sarcoidosis, which had not been evident on chest x-ray among patients with neurosarcoidosis.3
and chest CT. The patient was stabilized neurologically
Sarcoidosis-related vestibular dysfunction may occur
with methylprednisolone at 1,000 mg/day for 5 days. She as a result of vasculitis or granulomatous inflammawas discharged on prednisone at 60 mg/day.
tion of the vestibulocochlear nerves4,7 and perhaps by
On outpatient follow-up, rotational and caloric direct labyrinthine involvement.13 Auditory impairment
vestibular testing demonstrated severe bilateral loss of may be caused by granulomatous inflammation of the
peripheral vestibular function. The patient’s hearing arachnoid vessels, the cochlear nuclei, vestibulocochlear
remained intact, and no uveitis or periocular sarcoidosis nerves, or the labyrinth itself.10 Von Brevern et al found
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paroxysmal positional verti- A
B
cal nystagmus with absent
horizontal canal vestibular
responses.4 They suggested
that selective vestibular dysfunction may result from focal vasculitis. In a case report
by Babin et al, temporal bone
histology in a patient with
deafness showed prominent
Figure 2. A: The histologic section from the right temporal lobe biopsy demonstrates non-necrotizing
perivascular lymphocytic in- granulomatous inflammation consisting of nodular foci of numerous histiocytes, lymphocytes, and
filtration with degeneration plasma cells. A multinucleated giant cell (MNGC) is also seen (DAB and hematoxylin, original magof nerve axons and myelin.14 nification ×100). B: At higher power, a noncaseating granuloma (arrows) demonstrates mononuclear
The authors hypothesized histiocytes admixed with an MNGC (DAB and hematoxylin, original magnification ×400).
that sarcoidosis in this area
6. Agari D, Koide R, Kashiyami T, et al. Neurosarcoidosis: A treatable
begins as a reversible neuropathy and evolves over time
cause of vestibular dysfunction. Lancet 2007;369(9564):878.
to an irreversible degeneration of neuroepithelium and
7. Garcia Berrocal JR, Trinidad A, Vargas JA, et al. Sudden hearing
nerve elements. In our patient, vestibular function never
loss and uveitis as a form of presentation of neurosarcoidosis [in
Spanish]. Acta Otorrinolaryingol Esp 1998;49(6):488-90.
returned, although it is possible that corticosteroids
8. Sugaya F, Shijubo N, Takahashi H, Abe S. Sudden hearing loss as the
had been administered too late in the clinical course to
initial manifestation of neurosarcoidosis. Sarcoidosis Vasc Diffuse
Lung Dis 1996;13(1):54-6.
induce a recovery.
9. Sakakibara R, Nakajima M, Hirayama K, Yagihashi M. PsychoParenchymal mass lesions have been seen in neurosarneurological symptoms and raised angiotensin-converting enzyme
coidosis, and they may mimic gliomas or lymphoma.15
in cerebrospinal fluid in a patient with sarcoidosis beginning in the
central nervous system. Rinsho Shinkeigaku 1990;30(11):1227-31.
Our patient developed both an anterograde and tem10. Moine A, Frachet B, Van Den Abbeele T, et al. Deafness and sarcoiporally graded retrograde amnesia that was clinically
dosis. Ann Otolaryngol Chir Cervicofac 1990;107(7):469-73.
and radiographically consistent with the syndrome of 11. Mende D, Suchenwirth RM. Neurosarcoidosis. Comparative analysis
of the clinical profile based on 537 cases from the world literature
bitemporal amnesia.16 A normal chest x-ray, chest CT,
up to 1963 and from 1976-1988. Fortschr Neurol Psychiatr 1990;58
and serum ACE level do not exclude the possibility of
(1):7-18.
neurosarcoidosis.17,18 A tissue biopsy may be the only 12. Hybels RL, Rice DH. Neuro-otologic manifestations of sarcoidosis.
Laryngoscope 1976;86(12):1873-8.
means of making the diagnosis in such instances.19 13. Avilés Mañoso P, Juan Ivars C, Portell Soriano M, Ramos Fernández J.
A gallium scan20 or whole-body positron-emission
Neurosarcoidosis. Sensorineural hearing loss. Acta Otorrinolaringol
Esp 1997;48(3):229-31.
tomography17,21 may also help with the diagnosis if
14. Babin RW, Liu C, Aschenbrener C. Histopathology of neurosensory
changes are seen in the pulmonary hila or salivary glands,
deafness in sarcoidosis. Ann Otol Rhinol Laryngol 1984;93(4 Pt 1):
389-93.
and such imaging may direct the location for a biopsy.
15. Seriès C, Jarnier D, Cohadon F, et al. An unusual form of neuroCorticosteroids may be used empirically but with causarcoidosis isolated in association with a tumoral lesion, chronic
tion, and every attempt should be made to confirm a
meningitis, hydrocephalus and hypothalamo-hypophyseal involvement [in French]. Neurochirurgie 1999;45(3):243-6.
diagnosis because some neurologic manifestations of
16. Squire LR. The neuropsychology of human memory. Annu Rev
sarcoidosis may fail to improve with steroids and require
Neurosci 1982;5:241-73.
17. Dubey N, Miletich RS, Wasay M, et al. Role of fluorodeoxyglucose
more aggressive immunomodulating drugs.22
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